Loading...
Market
First Targeted Coronavirus Type for Quartet Nanocage Vaccine by 2025
5
Resolution / Starting Odds
Known Human Coronavirus • 33%
Animal Coronavirus • 33%
Newly Discovered Coronavirus • 34%
Guidelines released by health authorities such as the CDC or WHO
Story
Cambridge Uni's 'Quartet Nanocage' Vaccine Targets All Coronaviruses
May 6, 2024, 03:25 PM
Researchers at Cambridge University have developed a groundbreaking vaccine technology, known as proactive vaccinology, which offers protection against a wide range of coronaviruses, including those not yet discovered. This new approach utilizes a 'quartet nanocage' structure to build immunity against potential future pathogens. The vaccine has shown effectiveness in mice and is designed to preemptively combat the threats of upcoming pandemics.
View original story
Similar markets
Pharmaceutical Company • 33%
University Research Team • 33%
Government Health Agency • 34%
USA • 25%
UK • 25%
China • 25%
Canada • 25%
Yes • 50%
No • 50%
Pfizer • 33%
Moderna • 33%
Other • 34%
Positive impact • 33%
No significant impact • 34%
Negative impact • 33%
Pre-clinical • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
